Jacobio’s IND Accepted for Phase I/II Trial of BET Inhibitor JAB-8263
Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of...
Tag : autoimmune disease
Vor Bio, RemeGen Ink Autoimmune Deal, Raise $175M in Funding
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted...
Harbour BioMed, Otsuka Partner on BCMAxCD3 T-Cell Engagers
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a...
Keymed’s CM336 Trial Results Published in NEJM
Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi’s research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of...
Everest Medicines Shares Positive Early Data on BTK Inhibitor EVER001
Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced...
Topas Therapeutics Publishes Data on Tolerance Induction Platform
Topas Therapeutics today announced the publication of data highlighting the ability of its proprietary antigen-coupled nanoparticles’ to achieve tolerance induction in relevant autoimmune disease models, under...